Listing 3 - Actual negotiations

Indication:

For the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated locally advanced unresectable or metastatic pancreatic adenocarcinoma whose disease has not progressed on prior systemic therapy

Indication:

For treatment of adult and pediatric (12 years and older) patients with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL)

Indication:

For the topical treatment of plaque psoriasis of the scalp and body in patients 12 years of age and older.

Indication:

Chronic Obstructive Pulmonary Disease (COPD)

Indication:

For the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids, or who have experienced a relapse during corticosteroid taper.

Indication:

For the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and pediatric patients 3 years of age and older and weighing ≥12 kg.

Indication:

As an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal emoglobinuria (PNH) who have residual hemolytic anemia due to extravascular hemolysis (EVH)

Indication:

For once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus: As monotherapy when metformin is inappropriate due to contraindication or intolerance. In combination with: metformin, or metformin and a sulfonylurea, or metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i), or basal insulin with or without metformin.

Indication:

To increase linear growth in patients with achondroplasia who are 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Indication:

For the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained greater than or equal to 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering greater than or equal to 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.